• Served as subject matter expert in the development of well characterized pre-clinical ligand-binding immunoassays that quantitate IgG response to target polysaccharides and proteins expressed by Gram negative bacteria to drive early research decisions, establish proof-of-concept and select vaccine antigens• Supported development of live-cell neutralization assays to evaluate challenge model immunogenicity studies, which extended to bacterial bank preparation and monitoring of target antigen expression via flow cytometer• Developed an exploratory urine qPCR to measure neutralizing capacity of antigen-specific antibodies• Adopted MSD U-PLEX technology for drug substance/drug product analytics of glycoconjugates• Evaluated proteolytic activity of Gram positive bacteria conserved enzymes via FRET and SDS-PAGE• Integrated Bravo Agilent programming with 2D barcode labware to maximize automation resources• Authored various detailed development reports to support patent filing and published manuscripts

• Served as project lead and managed cross-departmental colleagues in the development and pre-qualification of direct Luminex immunoassays for the quantitation of viral envelope protein specific IgG to determine go-forward mRNA formulations; presented to partner institutions and served as an on-call advisor• Performed investigations to determine mechanism of action including whether a pathogenic spirochete binds human plasminogen via outer surface proteins by characterization of their binding affinity via Octet• Developed an exploratory competitive-inhibition immunoassay to quantitatively measure functional antibodies to evaluate candidate vaccine efficacy relative to competitor biosimilar

• Served as project lead for the development and qualification of multiplexed serological assays for the quantitation of antibodies against target Gram positive bacteria antigens; performed analytical method transfer overseas to establish a standardized direct Luminex immunoassay under Gates Foundation consortium • Executed statistical experimental design to evaluate assay robustness and linearity of dilution and to define limits of quantification via standard curve bias and measurable range to build SAS parameters• Lead the development and qualification of Luminex assays that quantitate antibody response to viral membrane fusion proteins and non-vaccine antigen